Skip to Main Content

Whither accelerated approval?

Amid the hubbub over new Medicare coverage restrictions for Alzheimer’s treatments, a key issue may not be fully appreciated: There is now bona fide pushback against accelerated approval, a controversial strategy used by regulators and companies to get new drugs to market faster than usual.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment